SLGLSol-Gel Technologies, Ltd.Finished
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Gorlin Syndrome
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 113 (final count)
- Started
- Mar 17, 2024
- Main results expected
- Aug 20, 2026
- Fully finished
- Sep 14, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of new BCCs on the face at Month 12
Measured over: Month 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06050122 · record last updated 2026-09-18 · checked 2026-11-09 15:36 UTC